Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Mesoblast Limited ( (AU:MSB) ) just unveiled an announcement.
Mesoblast Limited has announced the application for the quotation of 97,680,000 ordinary fully paid securities on the Australian Securities Exchange (ASX), with an issue date slated for January 20, 2025. This move is part of a transaction previously announced and is expected to further enhance the company’s liquidity and market presence, potentially impacting its stakeholders by expanding access to capital markets.
More about Mesoblast Limited
Mesoblast Limited is a biotechnology company focused on developing and commercializing innovative cellular medicines. It operates primarily in the biopharmaceutical industry, with a specialization in regenerative medicine and stem cell therapies.
YTD Price Performance: 1.82%
Average Trading Volume: 96,460
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $1.84B
For a thorough assessment of MSB stock, go to TipRanks’ Stock Analysis page.
